Mitoxantrone Etoposide and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC, works in individuals with either relapsed or refractory AML
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) plus Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
- ClinicalTrials.gov Identifier: NCT03118466
- Protocol Number: 16-574
- Principal Investigator: Lourdes Mendez
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required